United Therapeutics Corporation (NASDAQ:UTHR) has earned an average recommendation of “Hold” from the sixteen brokerages that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $127.80.

A number of research analysts have recently issued reports on the stock. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Wedbush reaffirmed an “outperform” rating and set a $213.00 target price (down previously from $229.00) on shares of United Therapeutics Corporation in a report on Thursday, April 27th. Cowen and Company reaffirmed a “hold” rating and set a $121.00 target price on shares of United Therapeutics Corporation in a report on Wednesday, April 26th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, ValuEngine lowered shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th.

In related news, CEO Martine A. Rothblatt sold 1,265 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $119.40, for a total value of $151,041.00. Following the sale, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at approximately $167,757. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Dwek sold 3,490 shares of the business’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total transaction of $459,667.90. The disclosure for this sale can be found here. Insiders sold a total of 24,649 shares of company stock worth $3,192,423 over the last ninety days. 7.80% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of UTHR. HPM Partners LLC boosted its stake in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 15 shares during the period. First Allied Advisory Services Inc. boosted its stake in shares of United Therapeutics Corporation by 0.4% in the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after buying an additional 19 shares during the period. Nomura Asset Management Co. Ltd. boosted its stake in shares of United Therapeutics Corporation by 0.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after buying an additional 40 shares during the period. Fisher Asset Management LLC boosted its stake in shares of United Therapeutics Corporation by 1.4% in the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 45 shares during the period. Finally, Argent Capital Management LLC boosted its stake in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 60 shares during the period.

Shares of United Therapeutics Corporation (UTHR) traded up 1.13% during mid-day trading on Tuesday, reaching $131.28. The company’s stock had a trading volume of 433,488 shares. The stock has a market capitalization of $5.70 billion, a P/E ratio of 15.22 and a beta of 1.51. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The company has a 50 day moving average price of $130.38 and a 200 day moving average price of $133.65.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The business had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.42 EPS. On average, equities research analysts anticipate that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

United Therapeutics Corporation announced that its board has approved a stock repurchase plan on Thursday, April 27th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to purchase up to 4.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Receives Average Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/22/united-therapeutics-corporation-uthr-receives-average-rating-of-hold-from-analysts.html.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.